High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
about
Cancer as an evolutionary and ecological processClinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemiaProgress in acute myeloid leukemiaSignature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcomaGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersCharacteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanismsCopy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.Glycoside hydrolases in Aplysia fasciata: analysis and applications.Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of SapacitabineGemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.ABC transporters and their role in nucleoside and nucleotide drug resistance.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Gene set analysis of purine and pyrimidine antimetabolites cancer therapiesPreclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine).Concise total synthesis of two marine natural nucleosides: trachycladines A and B.New treatments and strategies in acute myeloid leukemia.Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification.Prognostic factors in canine acute leukaemias: a retrospective study.Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.Acute myeloid leukemia in children: Current status and future directions.Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working PaF14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis.
P2860
Q22122026-EC45867C-C994-477A-A257-B3589C0C3FEAQ24621923-D1D09EBE-52DF-46F9-B52D-1B610250A95EQ27024006-C7A38A68-4C38-451E-9526-17F38D7AAA34Q28469179-58813844-0B87-473B-A949-C51069206AC4Q28471821-5B884F4B-96F7-4EE3-AE27-5F362F1460FCQ33392185-A59C34AC-0619-4897-B74F-88BBFCDA708FQ33392660-83D2595A-6AA6-4553-A657-FA2989921563Q33595261-86BCFC82-EFBA-46E3-9FA8-248DA097D9BBQ33698015-45AB7705-E6D8-48D0-939C-FB2F1FFD1000Q33848920-36E8F00B-A306-4139-8B09-0AAB134FE747Q33877213-BEB6A33C-A58F-41CA-B852-8B92354C62A8Q33949752-A22201F8-3348-47C1-922E-2BE1F3329ED3Q34317679-05BAE783-172B-4DA3-90D9-3DE21488EE93Q35209900-2BE15F1B-EBB0-4E44-A93B-7F89F7C1F672Q36289307-3300B244-03D2-4F8E-9B0A-A81A7BC3C306Q36924856-9AF45BD6-C17B-4C19-9594-6CE3A2729524Q37271941-E646F21D-0D65-42CF-9653-80BCB2416933Q37595491-DA20B952-DD80-4252-96C4-962A9DB212B1Q37979617-F0413A07-1A70-4209-83FC-2D60E76E6982Q38644941-0CE502CB-7585-4C69-AB1B-85F34EB91633Q38690391-61EC183A-4733-47A0-93C5-19C21ED3230EQ39280587-8650C979-A069-4E14-9A16-5B9372776B4AQ39373653-2DB99602-FEA9-4762-A0B8-59CF7BBEDAEDQ41836721-5E58FF84-6BE8-4C37-B24E-835E1232954FQ41881090-C8A07053-F398-4C5B-8A6C-25ABF342966AQ42720213-A494CB63-B458-43BD-AD1B-8FA712D3FFFFQ42721533-13095DCA-87CC-4CB4-A031-E284AB4F0FFFQ42826040-94ABB557-7B62-4D47-B260-B81C4EEED222Q44264067-DA41B798-92E6-443B-BD89-698B1347197EQ48231999-544C93FA-11C4-42CF-AC32-AF023DADB803Q48328410-10B1C487-D937-49EC-B22F-4060F524D92EQ50923400-CAFAF51C-1029-4296-87F6-9D335E182B30Q52897332-EA2603A3-9AEF-4325-B991-B9A669FD2B5CQ53132420-ADEF1EB1-8F1B-4641-898C-D78AFF7939C3Q54264719-D45E6928-90D1-4BD4-A06E-A3245672C2BAQ54575239-FBEBC86C-294B-4993-A354-284E194F8AAE
P2860
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High-dose cytosine arabinoside ...... ew of three randomized trials.
@ast
High-dose cytosine arabinoside ...... ew of three randomized trials.
@en
High-dose cytosine arabinoside ...... ew of three randomized trials.
@nl
type
label
High-dose cytosine arabinoside ...... ew of three randomized trials.
@ast
High-dose cytosine arabinoside ...... ew of three randomized trials.
@en
High-dose cytosine arabinoside ...... ew of three randomized trials.
@nl
prefLabel
High-dose cytosine arabinoside ...... ew of three randomized trials.
@ast
High-dose cytosine arabinoside ...... ew of three randomized trials.
@en
High-dose cytosine arabinoside ...... ew of three randomized trials.
@nl
P356
P1433
P1476
High-dose cytosine arabinoside ...... ew of three randomized trials.
@en
P2093
Elihu H Estey
Wolfgang Kern
P304
P356
10.1002/CNCR.21543
P407
P577
2006-07-01T00:00:00Z